©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Oct 26, 2025; 17(10): 110072
Published online Oct 26, 2025. doi: 10.4330/wjc.v17.i10.110072
Published online Oct 26, 2025. doi: 10.4330/wjc.v17.i10.110072
Pharmacological interventions to enhance exercise capacity in patients with heart failure
Ryo Naito, Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan
Author contributions: Naito R wrote and revised the manuscript.
Conflict-of-interest statement: No conflict of interest on this review.
Corresponding author: Ryo Naito, MD, MSc, PhD, Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, 2‐1‐1 Hongo Bunkyo‐ku, Tokyo 113-8421, Japan. rnaitou@juntendo.ac.jp
Received: May 28, 2025
Revised: June 11, 2025
Accepted: September 1, 2025
Published online: October 26, 2025
Processing time: 149 Days and 1.3 Hours
Revised: June 11, 2025
Accepted: September 1, 2025
Published online: October 26, 2025
Processing time: 149 Days and 1.3 Hours
Core Tip
Core Tip: Heart failure (HF) affects quality of life and prognosis in patients with HF. Although cardiac rehabilitation is an effective intervention to improve exercise intolerance in patients with HF. Cardiac rehabilitation is not always accessible because of restricted access for those who need rehabilitation. Evidence on pharmacological interventions to improve exercise capacity in patients with HF is scarce. This mini-review summarizes available evidence on the effects of pharmacological therapy for HF on improving exercise capacity.